Immune Mechanisms in Arterial Hypertension

Ulrich Wenzel,* Jan Eric Turner,* Christian Krebs,* Christian Kurts,† David G. Harrison,‡ and Heimo Ehmke§

*Department of Medicine and  †Department of Cellular and Integrative Physiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;  §Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms University, Bonn, Germany; and  ‡Division of Clinical Pharmacology, Department of Medicine, Nashville, Tennessee

ABSTRACT

Traditionally, arterial hypertension and subsequent end-organ damage have been attributed to hemodynamic factors, but increasing evidence indicates that inflammation also contributes to the deleterious consequences of this disease. The immune system has evolved to prevent invasion of foreign organisms and to promote tissue healing after injury. However, this beneficial activity comes at a cost of collateral damage when the immune system overreacts to internal injury, such as prehypertension. Renal inflammation results in injury and impaired urinary sodium excretion, and vascular inflammation leads to endothelial dysfunction, increased vascular resistance, and arterial remodeling and stiffening. Notably, modulation of the immune response can reduce the severity of BP elevation and hypertensive end-organ damage in several animal models. Indeed, recent studies have improved our understanding of how the immune response affects the pathogenesis of arterial hypertension, but the remarkable advances in basic immunology made during the last few years still await translation to the field of hypertension. This review briefly summarizes recent advances in immunity and hypertension as well as hypertensive end-organ damage.


Hypertension is the most common modifiable risk factor for cardiovascular disease and death. Worldwide, it is estimated that >1 billion adults have hypertension, and this figure is projected to climb to 1.5 billion by the year 2025. An improved understanding of the mechanisms underlying arterial hypertension and its subsequent damage to the kidneys, heart, and vascular system is clearly needed. For many years, it was believed that hypertensive end-organ damage is merely the result of an increased hydrostatic pressure on the vessel walls. Indeed, in 1977 Beilin stated that pressure, if it is great enough, will eventually disrupt any structure.¹ In intact vessels, pressure mediates cellular stretch, which can in turn lead to cell death and initiate a tissue response aimed at removing dead cells and replacing them to restore homeostasis. These repair processes are a substantial component of the immune response, and it is therefore self-evident that activation of both the innate and adaptive arm of the immune system occurs in arterial hypertension.

A hint for a role of the immune system in hypertension was the observation that pressor doses of angiotensin II (Ang II) administered for a short time period resulted in subsequent salt-sensitive hypertension and renal infiltration and activation of immune cells. Both of these sequelae were reduced by immunosuppression.² The concept that inflammation is not only a consequence of the physically induced injury but also a cause of hypertension, was further supported in a 2007 study.³ That study found that the increase in BP caused by Ang II infusion was significantly blunted in mice lacking the recombinase-activating gene 1 (RAG-1¹⁻⁄⁻ mice), a strain that lacks T and B cells. In these experiments, adoptive transfer of T cells, but not B cells, restored the hypertensive response,³ indicating that T cells play an important role in generation of arterial hypertension. These results have been confirmed in severe combined immunodeficiency mice and in Dahl salt-sensitive rats in which the RAG-1 or the essential T cell receptor component CD3 have been deleted using zinc finger nuclelease technology.⁴–⁶ This seminal work has caused great interest in the immunologic aspects of hypertensive disease.⁷–¹⁰

This review will give a brief overview of the components of the innate and adaptive arm of the immune system in hypertension and summarize recent advances in immunologic research, with a special focus on their potential relevance for hypertension and hypertensive end-organ damage. Very recent findings on the role of dendritic cells as well as CD8⁺...
and T_{h}17 T cells in hypertension will be discussed.

**INNATE IMMUNITY**

Innate immunity is considered to be the immune system’s first line of defense against invading pathogens. The term “innate” refers to the inherent capacity of this arm of immune defense to be rapidly activated by external stimuli without need for time-consuming, antigen-specific education or interaction with other cells. The essential cellular components of innate immunity are granulocytes, macrophages, mast cells, and certain subsets of lymphocytes, whereas the most important humoral component beside the defensin system is the complement system.

**Complement**

The complement system is one of the oldest components of immunity and is central to the detection and destruction of invading pathogens. It is a system of fluid-phase and cell membrane–bound proteins. Complement activation produces anaphylatoxins, such as C3a and C5a, which are chemotactic stimuli and can activate a variety of immune effector cell types. Both C3a and C5a serum levels are significantly increased after induction of hypertension by Ang II infusion. Interestingly, hearts of C5a knockout mice are protected from hypertensive cardiac inflammation. Moreover, treatment with a C5aR antagonist also prevented cardiac remodeling in Ang II–induced hypertension.

**Reactive Oxygen Species**

While there are several reactive oxygen species (ROS)-producing enzymes in mammalian cells, a major source are the nicotinamide adenine dinucleotide phosphate–(NADPH) oxidases. Professional phagocytes use the NADPH oxidase to produce superoxide and kill invading organisms. Superoxide serves as a progenitor for numerous other ROS, including hydrogen peroxide, hydroxyl radical, and peroxynitrite. The NADPH oxidases have evolved to have numerous roles in other cells, including modulation of sympathetic outflow, vascular tone, and renal sodium reabsorption, all of which contribute to hypertension. The sympathetic nervous system and hypothalamic pituitary axis are two major pathways in which the NADPH oxidases modulate neuroimmune communication. The sympathetic nervous system innervates both primary (thymus, bone marrow) and secondary tissues and lymphoid tissues (spleen, lymph nodes), and most immune cells express receptors for neurohormones and catecholamines. Inhibition of the NADPH oxidase subunit p22^{phox} in the subfornical organ eliminated the Ang II–induced hypertensive response and vascular inflammation. In addition, a peripheral neuroimmune response in the spleen, mediated by celiac ganglion efferent nerve fibers, is essential for the development of hypertension. The NADPH oxidase in antigen-presenting cells plays a role in their activation in hypertension, and inhibition of this enzyme blunts the vascular inflammation present in hypertension.

**Innate Sensing of Injury**

Signature molecules of microbial origin (pathogen-associated molecular patterns) or molecules that are released by host cells in response to stress or damage (damage-associated molecular patterns [DAMPs]) can activate resident and innate immune cells via action on many germline-encoded pattern recognition receptors (PRRs). The inflammatory response to cell stress or injury has been called “sterile inflammation.” The best-characterized pattern recognition receptors of the immune system are toll-like receptors (TLRs). These are expressed on a variety of immune and somatic cells and are activated by a variety of pathogen-associated molecular patterns and DAMPs to initiate inflammatory responses. TLR4 was elevated in spontaneously hypertensive rats, and treatment with an anti-TLR4 antibody lowered BP in this model. TLR4 is also increased in cardiomyocytes of the spontaneously hypertensive rat and angiotensin-converting enzyme inhibition lowers its expression. G-nitro-L-arginine-methyl ester (L-NAME)–induced hypertension is blunted in TLR4-deficient mice. TLR9 is expressed in aortic vascular smooth muscle cells, and its activation augments contractile responses in conduit arteries. Activation of nicotinic acetylcholine receptors in splenocytes inhibits TLR-mediated inflammation in Wistar-Kyoto rats but paradoxically increases inflammation in the SHR. TLRs likely represent a link between host-derived “danger” molecules (DAMPs), low-grade inflammation, vascular remodeling, and hypertension. This topic has recently been reviewed in detail.

**Inflammasome**

Some pattern recognition receptors trigger a distinct proinflammatory mechanism that involves assembly of cytosolic protein complexes called inflammasomes. Once assembled, inflammasomes activate caspase-1, which in turn processes the proinflammatory IL-1 family cytokines IL-1β and IL-18 from their inactive to their active forms. A well described stimulus for inflammasome activation involves the action of extracellular ATP on the P2X7 receptor. Cellular damage increases extracellular ATP, which in turn serves as a danger signal that ultimately stimulates IL-1 release. Interestingly, P2X7-deficient mice develop blunted hypertension in response to deoxycorticosterone acetate (DOCA) salt challenge, suggesting that the inflammasome is involved in the pathogenesis of hypertension. Other stimuli for inflammasome activation include cholesterol and uric acid crystals. Current studies of mice lacking components of the inflammasome promise to provide additional insight into the role of inflammation in hypertension.

**Monocytes/Macrophages and Other Bone Marrow–Derived Cells**

Cells of myeloid lineage, including macrophages, granulocytes, and dendritic cells, are major effectors of the innate immune system. Selective ablation of lysozyme M-positive myelomonocytic cells markedly blunts Ang II–induced infiltration of these cells into the vascular wall and attenuates Ang II–induced hypertension and vascular dysfunction.
Osteopetrotic (Op/Op) mice, in which macrophages are functionally deficient, exhibit reduced hypertension and vascular remodeling in response to Ang II or DOCA salt.\textsuperscript{31,32} As in the case of other immune cells, the bone marrow is the source of circulating monocytes, monocyte-derived dendritic cells, and most inflammatory macrophages. Of interest, bone marrow transplant studies have emphasized the role of the bone marrow in hypertension. Santisteban et al. have recently shown that transplant of marrow from spontaneously hypertensive rats to Wistar-Kyoto rats increases BP in the latter.\textsuperscript{33} Likewise, Saleh et al. showed that transplant of marrow from LNK\textsuperscript{-/-} mice, which are prone to inflammation and hypertension, markedly enhances the response to low-dose angiotensin II infusion in wild-type recipient mice.\textsuperscript{34}

**Lymphocytes of the Innate Immune System**

Natural killer (NK) cells are the classic effector lymphocytes of the innate immune system.\textsuperscript{35} Only in the last few years has another population of lymphocytes that belongs to the innate arm of the immune system been identified and studied extensively. Because of their antigen-independent activation and lymphoid morphology, these cells have been called “innate lymphoid cells” (ILCs). NK cells share characteristics of innate lymphoid cells and, according to the most recent nomenclature of these cells, are considered to be “killer” ILCs.\textsuperscript{36}

**Innate Lymphoid Cells**

NK cells (or “killer” ILCs) recognize stressed and damaged cells by a repertoire of activating and inhibitory NK cell receptors. Upon activation, NK cells exert cytotoxic effects on target cells. In Ang II–induced hypertension, NK cells migrate into the aortic wall and become a local source for interferon-\(\gamma\). Depletion of NK cells reduces Ang II–induced vascular dysfunction.\textsuperscript{37} The family of “nonkiller” ILCs, which are also called “helper-like” ILCs, can be further divided into three groups that differ in their cytokine production, transcription factor usage, tissue localization, and functional characteristic.\textsuperscript{36,38,39,40} The role of these cells in hypertension remains undefined.

**Innate-Like T Cell Subsets**

It has become evident that certain T cell subsets that bear T cell receptors with a restricted repertoire can be activated independently from antigen directly by cytokine stimuli. Therefore they are regarded as being on the border between innate and adaptive immunity. These “innate-like” T cells include \(\gamma\delta\) T cells, NK T cells, and mucosa-associated invariant T cells.\textsuperscript{41} The \(\gamma\delta\) T cells are a population of cells that express the T cell receptor \(\gamma\delta\) chains. \(\gamma\delta\) T cells are a major source of IL-17 in hypertension, as discussed below. The other cells have not been examined in arterial hypertension.

**ADAPTIVE IMMUNITY**

B cells, CD4\(^{+}\) cells, and CD8\(^{+}\) T cells are the major effectors of the adaptive immune system. As noted above, studies of RAG-1–deficient mice demonstrated that T cells contribute to the development of hypertension. On the basis of their cytokine production profile and expression of specific transcription factors, CD4\(^{+}\) T cells are classified into four major subsets: T\(_{H1}\), T\(_{H2}\), T\(_{H17}\), and regulatory T cells (Tregs) (Figure 1). The evidence for a role of the four subtypes in hypertension is summarized in Table 1.

**T\(_{H1}\) and T\(_{H2}\)**

Substantial evidence suggests that hypertension skews T cells toward a pro-inflammatory T\(_{H1}\) phenotype, as indicated by increased production of the T\(_{H1}\) cytokine IFN-\(\gamma\) and a decrease in T\(_{H2}\)-mediated responses.\textsuperscript{42} The T\(_{H1}\) response in hypertension has been examined with different gene deletion approaches, and these studies suggest that IFN-\(\gamma\) and T\(_{H1}\) polarization contributes to the hypertension and end-organ damage caused by angiotensin II or DOCA salt hypertension challenge.\textsuperscript{37,43–46} Data on T\(_{H2}\) in hypertension are lacking. In one study, treatment with IL-4 antibodies lowered BP in NZB mice.\textsuperscript{46}

**T\(_{H17}\)**

IL-17 is the defining cytokine of T\(_{H17}\) cells. Several isoforms of IL-17 exist, with IL-17A and -F being the most abundant. Ang II infusion increases IL-17A production by T cells and IL-17 protein in the aortic media and the heart.\textsuperscript{47} The initial hypertensive response to Ang II infusion is similar in IL-17A\(^{-/-}\) mice and wild-type mice. However, hypertension is not sustained in IL-17A\(^{-/-}\) mice.
### Table 1. Evidence for a role of the four subtypes in hypertension

<table>
<thead>
<tr>
<th>Variable</th>
<th>T&lt;sub&gt;H1&lt;/sub&gt;</th>
<th>T&lt;sub&gt;H2&lt;/sub&gt;</th>
<th>T&lt;sub&gt;H17&lt;/sub&gt;</th>
<th>Treg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Function</td>
<td>Intracellular bacteria, cell mediated autoimmunity</td>
<td>Helminth infections, allergic disease</td>
<td>Extracellular bacteria, fungi, cell mediated autoimmunity</td>
<td>Downregulation of the immune response in autoimmunity and infection</td>
</tr>
<tr>
<td>Observations in experimental arterial hypertension</td>
<td>Increased IFN-γ production in Ang II-induced hypertension&lt;sup&gt;42&lt;/sup&gt;</td>
<td>Decreased IL-4 production in Ang II-induced hypertension&lt;sup&gt;42&lt;/sup&gt;</td>
<td>Increased IL-17a production in Ang II-induced hypertension (plasma, aorta, heart)&lt;sup&gt;47–49&lt;/sup&gt;</td>
<td>Number of T&lt;sub&gt;H17&lt;/sub&gt; cells in kidney of hypertensive mice&lt;sup&gt;55&lt;/sup&gt;</td>
</tr>
<tr>
<td>Effect of knockout</td>
<td>IFN-γ deficiency has no effect on BP or albuminuria in Ang II-infused mice&lt;sup&gt;44&lt;/sup&gt;</td>
<td>No data</td>
<td>IL-17a deficiency lowers BP and reduces hypertensive injury in response to Ang II infusion&lt;sup&gt;47–49&lt;/sup&gt;</td>
<td>Not done because Treg knockout is lethal</td>
</tr>
<tr>
<td></td>
<td>IFN-γ receptor deficiency has no effect on BP leads to but less cardiac injury and mixed results in the kidney in response to Ang II infusion&lt;sup&gt;45&lt;/sup&gt;</td>
<td>IL-17a and IL-23p19 deficiency enhances renal injury in response to DOCA+Ang II infusion&lt;sup&gt;55&lt;/sup&gt;</td>
<td>IL-6 deficiency lowers BP and endothelial dysfunction in response to Ang II infusion&lt;sup&gt;52,53&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IFN-γ deficiency lowers BP in response to low-dose Ang II&lt;sup&gt;43&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T-bet- and IFN-γ deficiency have no effect on BP but less vascular dysfunction in response to Ang II infusion&lt;sup&gt;37&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effect of neutralizing antibodies</td>
<td>IFN-γ-antibody has no effect on BP in hypertensive NZB mice&lt;sup&gt;46&lt;/sup&gt;</td>
<td>IL-4 antibody reduces BP in hypertensive NZB mice&lt;sup&gt;46&lt;/sup&gt;</td>
<td>No effect of IL-17 and IL-23 antibody in response to Ang II infusion&lt;sup&gt;45&lt;/sup&gt;</td>
<td>No data</td>
</tr>
<tr>
<td>Effect of overexpression or administration</td>
<td>Overexpression of IFN-γ induces vascular dysfunction&lt;sup&gt;37&lt;/sup&gt;</td>
<td>No data</td>
<td>Overexpression of IL-17a in the skin induces hypertension&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Administration of IL-17 increases BP&lt;sup&gt;50&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>T-bet, T-box expressed in T cells.</sup>
reaching levels 30 mmHg lower than in wild-type mice by 4 weeks of Ang II infusion.48 In addition, mice lacking IL-17A are also protected against aortic stiffening and cardiac fibrosis after infusion of Ang II.47,49 Obviously, γδ T cell–derived IL-17 mediates the adverse effects of IL-17 in hypertension.45 In addition, IL-17 treatment increased systolic BP in mice.50 Tfh cells need IL-23 for expansion and survival. IL-23 receptor antibody treatment or IL-17A antibody treatment of Ang II–infused mice showed no major effect on cardiac or renal injury.45 It has to be kept in mind that antibody treatment never has an efficiency of 100%, whereas a genetic approach knocks down the gene and protein of interest to 0%. Dermal overexpression of IL-17A induces not only psoriasis-like lesions but also endothelial dysfunction, vascular oxidative stress, and arterial hypertension.51 The importance of IL-17 in hypertension is supported by studies of IL-6–deficient mice. IL-6 is needed for polarization of Tfh cells, and mice lacking this cytokine have lower BP and less endothelial dysfunction in response to Ang II infusion.52,53 IL-6 may also increase BP by stimulating epithelial sodium channels in collecting duct cells.54 Interestingly, in response to a combination of high-level Ang II infusion and DOCA salt administration, IL-17 deficiency can have adverse effects. Significantly higher renal injury was also found in IL-23p19–deficient mice with DOCA+Ang II–induced hypertension.55 In contrast, neither IL-17A nor IL-23p19 deficiency changed the degree of cardiac injury. Collectively, these findings show that IL-17 plays a major role in the pathophysiology of hypertension and hypertensive end-organ damage. A different role is possible in models with severe hypertensive end-organ damage, such as the combination of DOCA salt and Ang II.

T helper cells were originally considered to have stable phenotypes without changing of cytokine expression. However, experiments with Tfh cells in particular displayed dramatic instability of IL-17 secretion in vitro56,57 and in an animal model of multiple sclerosis (experimental autoimmune encephalomyelitis).58,59 Plasticity of Tfh cells in cardiovascular diseases and the potential impact on BP and tissue damage has not been investigated so far.

A fascinating relation exists between salt intake and IL-17. Two independent studies showed that sodium chloride can exaggerate Tfh production by CD4+ T cells due to activation of the serum and glucocorticoid-regulated kinase 1, which stabilizes the IL-23 receptor and reinforces the Tfh phenotype.60,61 Thus, a decreased Tfh response may significantly contribute to the beneficial effects of salt restriction in patients with hypertension. Serum and glucocorticoid-regulated kinase 1 is also the link between salt intake and accelerated allograft rejection.62 Activation of renal sodium transporters is blunted in INF-γ and IL-17A–deficient mice in response to Ang II, suggesting that sodium transporters are an important link between IFN-γ and IL-17 and hypertension.43 Titze and coworkers identified another important link between sodium and the immune system. In a series of elegant experiments, these authors found that high salt intake promotes skin Na+ accumulation and that this in turn causes macrophages to produce factors including VEGF-C, which modulates skin interstitial lymphatic density.63 In addition, Na+ accumulates at the site of bacterial skin infections in humans and mice and boosts classic macrophage activation, thus helping to ward off skin infection. Thus, salt deposition might serve as an ancient mechanism to aid in immune-mediated pathogen removal.64

Tregs and IL-10

The main function of Tregs is maintenance of immunologic tolerance. Several groups have shown that adoptive transfer of Tregs lowers BP and ameliorates cardiac and renal injury in different models of hypertension.65–68 Mice deficient in IL-10, an important product of Tregs, develop similar degrees of hypertension in response to angiotensin II, but have severe endothelial dysfunction and vessels from these mice show an increased superoxide production when incubated with angiotensin II.69 These and other data suggest that Treg-derived IL-10 mediates the beneficial effects of Tregs in hypertension.70 IL-2/anti–IL-2 immune complex treatment of hypertensive mice expands Tregs and reduces aortic stiffness.71 Administration of IL-10 lowers BP in preeclampsia.72

CD8+ T Cells

Convincing evidence suggests that T cells contribute to BP elevation. A major question, however, is what T cells are doing to cause these effects. A recent study has suggested that CD8+ T cells are a major source of IFN-γ and that these accumulate in the kidney in hypertension. Mice lacking CD8+ T cells developed blunted hypertensive responses to Ang II, while mice lacking CD4+ cells are not similarly protected. Vascular rarefaction in the kidney was noted in wild-type and CD4+–/– mice, but not in CD8+–/– mice. This in turn could promote sodium and volume retention.73 It should be recognized that mice lacking CD4+ cells also lack Tregs and this perhaps predispenses these animals to worsened hypertension.

Antigens and Dendritic Cells

The canonical function of dendritic cells is activation of T cells.74 After acquiring antigens, dendritic cells process these to peptides, migrate to the secondary lymphoid organ, and present these antigenic peptides in the context of MHCs to T cells. Antigen-activated T cells proliferate and produce clones specific for the antigen. The kidney harbors a network of dendritic cells. “Neoantigens” might be produced in response to early hypertensive mechanical trauma injury by induction of cell death and release of intracellular antigens that normally are immune privileged. Interestingly, various hypertensive stimuli increase ROS production in dendritic cells by activation of the NADPH oxidase. This leads to lipid oxidation and formation of γ ketoaldehydes or isoketals. Isoketals rapidly ligate to protein lysines in the dendritic cells, forming proteins that are interpreted as nonself as shown in Figure 2. Peptides from these proteins are presented to T cells, leading to their proliferation. In addition, isoketal formation also promotes production of cytokines, including IL-1β, IL-6, and IL-23, which polarize T cells to produce effector
cytokines. Transfer of isoketal-activated dendritic cells raises BP in wild-type mice but not in RAG-1−/− mice that lack T cells. Moreover, treatment with isoketal scavengers blunts hypertension and its associated renal injury in mice. A role of dendritic cells in hypertension was also suggested by prior work using abatacept, which blocks CD80 and CD86 on dendritic cells. CD28 binds to these co-stimulatory molecules on dendritic cells and acts as a co-stimulatory receptor in the activation and maturation of T lymphocytes. Abatacept treatment reversed Ang II and DOCA salt–induced hypertension, confirming a role of T cell priming by dendritic cells in hypertension.

**Microbiome**

The human gut is the natural niche for >10^14 bacteria of >1000 different species. The microbiota seem to modulate immune responses, and increasing data show that alterations in the microbiota contribute to immune disorders and cardiovascular diseases. Interestingly, recent data have shown that short-chain fatty acids produced by gut microbiota modulate renin release by binding to olfactory receptors expressed in the renal juxtaglomerular apparatus. A link between microbial content and BP regulation was also found in Dahl S and R rats. The cross-talk between the gut microbiota and the renal and cardiovascular systems could be relevant to the

---

**Figure 2.** Role of dendritic cells as well as CD4+ and CD8+ cells in hypertension. Hypertension causes lipid oxidation in dendritic cells (DC) resulting in formation of isoketal adducts of various self-proteins. These isoketal-modified proteins behave like DAMPs and activate dendritic cells. The dendritic cells secrete cytokines such as IL-1, IL-6, and IL-23. In the renal lymph node or other tissues dendritic cells may activate CD8+ and CD4+ T cells that migrate into the kidney. CD8+ T cells release cytotoxins such as perforin and granzyme leading to apoptosis or cell death of peritubular capillaries causing vascular rarefaction. IL-17A and IFN-γ released from Th17 and Th1 cells activate the renin-angiotensin system and may stimulate or upregulate transport channels in the proximal and distal convoluted tubules, including the sodium hydrogen exchanger 3 (NHE3) and the sodium chloride cotransporter (NCC). Both in turn causes sodium and volume retention. Modified from reference 10.
MECHANISMS OF EXPERIMENTAL MODELS OF HYPERTENSION

How does the immune system cause hypertension? Convincing data demonstrate that inflammatory cytokines such as IL-17, IFN-γ, or IL-6 may modulate sodium reabsorption, as shown in Figure 2. In addition, infiltration of cytotoxic CD8 T cells into the renal interstitium may also lead to capillary rarefaction, as shown in Figure 2. The inflammation associated with hypertension also causes deposition of collagen in the aortic adventitia and media with a loss of Windkessel or capacitance function.49

Most data on hypertension and inflammation in mice have been obtained through Ang II or norepinephrine infusion with osmotic mini-pumps or DOCA salt treatment. These experimental interventions reproduce several features of human hypertension. Ang II infusion resembles the condition in hypertensive patients with an inappropriately activated renin-angiotensin system, whereas norepinephrine infusion mimics the state of patients with an increased sympathetic drive. DOCA salt treatment models use enhanced mineralocorticoid activity, which is increasingly recognized in patients with resistant hypertension and so-called low-renin hypertension, based on the efficacy of mineralocorticoid receptor blockade in these patients. Furthermore, new mouse models are necessary to investigate the influence of genetic variants conferring an increased susceptibility to hypertensive renal injury associated with hypertension, as demonstrated for the gene that encodes the molecular motor protein nonmuscle myosin 2a (MYH9).80

SUMMARY

Why should evolution favor immunity as a regulator of BP? Control of BP and host defense are essential mechanisms of homeostasis. Infection can cause hypertension via fluid loss in fever, tachypnea, and diarrhea. Septicemia induces inflammation-related vascular fluid losses. Thus, as suggested recently, the risk of hypotension related to inflammation might have favored selection of mechanisms that link immune activation to BP increases for short-term survival benefits. Such an evolutionary force may be responsible for the fact that important antimicrobial effectors such as IL-17 or ROS have direct hypertensive effects by vasoconstriction or sodium retention.81

Synthesis of all of the available evidence has led us to propose the following hypothesis as a mechanism for inflammation and hypertension (Figure 3). Small increases in prohypertensive factors, such as Ang II, salt retention, or aldosterone, activate the innate immune system that triggers or aggravates hypertension. This process includes complement activation and release of DAMPs that activate TLRs. These mechanisms can damage the kidney directly. Hypertensive stimuli also induce NADPH

Figure 3. Working hypothesis describing the role of immunity in hypertension. Hypertensive factors such as Ang II, salt, or aldosterone lead to a cascade of events: They directly activate the innate immune system. This process includes complement activation and release of DAMPs, which can activate toll-like receptors and also the inflammasome. On the one hand these mechanisms damage the kidney directly. On the other hand, they promote the release of cryptic antigens and ROS production, isoketal formation, and alteration of proteins in dendritic cells. These nonself recognized proteins are presented to T cells. Polarized CD4+ and CD8+ T cells migrate into the heart, vessels, and kidney and mediate the hypertensive end-organ damage or aggravate this damage, as in the case of kidney arterial hypertension due to salt and volume retention. In addition activation of cells, such as monocytes/macrophages, γδ T cells, NK cells and ILCs, may mediate or aggravate hypertensive renal injury. Modified from reference 7. CNS, central nervous system, nAg, neoantigen.
oxidase–dependent ROS production in dendritic cells, which leads to formation of neoantigens that can activate adaptive immune cells. Activation of innate-like lymphocytes, such as γδ T cells and NK cells, as well as the adaptive immune system, consequently aggravates renal injury. Our hypothesis will almost certainly require refinement as new information becomes available. Are there clinical consequences? The major reason to treat hypertension is to prevent end-organ damage. While BP-lowering is clearly important to reach this goal, prevention of hypertension is to prevent end-organ damage. While BP-lowering is clearly important to reach this goal, prevention of end-organ damage. While BP-lowering is clearly important to reach this goal, prevention of end-organ damage.

REFERENCES

BRIEF REVIEW

DISCLOSURES

None.

REFERENCES

32. Ciuculescu C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL: Reduced vascular


